ライフサイエンスコーパス: fluorine-18-fluorodeoxyglucose

1 changes in lower extremity venous uptake of fluorine-18-fluorodeoxyglucose.

2 minutes after injection of 370 MBq (10 mCi) fluorine 18 fluorodeoxyglucose ((18)F-FDG) followed by p

3 ough positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ((18)F-FDG) has a major i

4 al (IB) routes and imaged sequentially using fluorine-18 fluorodeoxyglucose ((18)FDG) uptake as a non

5 Histograms of administered activity for fluorine 18 fluorodeoxyglucose and iodine 131 sodium iod

6 aging, and positron emission tomography with fluorine 18 fluorodeoxyglucose and novel tracers.

7 s, positron emission tomography imaging with fluorine-18-fluorodeoxyglucose, and cardiac magnetic res

8 ermined with findings of decreased uptake of fluorine 18 fluorodeoxyglucose at PET, shrinkage of tumo

9 patients (20.7%) with adequate follow-up had fluorine 18 fluorodeoxyglucose-avid IMLN, with a median

10 CT scans is feasible and may be helpful when fluorine 18 fluorodeoxyglucose-avid masses that are not

11 Fluorine-18-fluorodeoxyglucose detected unsuspected meta

12 analysis, the role of metabolic imaging with fluorine 18 fluorodeoxyglucose (FDG) in breast cancer is

13 lculation of the percentage injected dose of fluorine 18 fluorodeoxyglucose (FDG) in tumor from small

14 PET with the labeled glucose analogue fluorine 18 fluorodeoxyglucose (FDG) is a relatively rec

15 out tumor metabolism, which is measured with fluorine 18 fluorodeoxyglucose (FDG) PET.

16 s and possible CS who were investigated with fluorine 18 fluorodeoxyglucose (FDG) PET/CT and cardiac

17 lly suspected underwent clinically indicated fluorine 18 fluorodeoxyglucose (FDG) PET/CT and, immedia

18 and to identify differences between WAT and fluorine 18 fluorodeoxyglucose (FDG) PET/CT proven cold-

19 he correlation between metabolic activity at fluorine 18 fluorodeoxyglucose (FDG) positron emission t

20 Purpose To assess the diagnostic accuracy of fluorine 18 fluorodeoxyglucose (FDG) positron emission t

21 It has been reported that fluorine 18 fluorodeoxyglucose (FDG) positron emission t

22 he established patterns of hypometabolism on fluorine 18 fluorodeoxyglucose (FDG) positron emission t

23 trinsic contrast of melanin in comparison to fluorine 18 fluorodeoxyglucose (FDG) positron emission t

24 cal-pathologic nodal status with use of four fluorine 18 fluorodeoxyglucose (FDG) positron emission t

25 baseline magnetic resonance (MR) imaging and fluorine 18 fluorodeoxyglucose (FDG) positron emission t

26 Fluorine 18 fluorodeoxyglucose (FDG) positron emission t

27 ively compare the sensitivity of a dedicated fluorine 18 fluorodeoxyglucose (FDG) positron emission t

28 luate the positive predictive value (PPV) of fluorine 18 fluorodeoxyglucose (FDG) positron emission t

29 aging technique in body imaging is currently fluorine 18 fluorodeoxyglucose (FDG) positron emission t

30 ss significant (P < .05) differences between fluorine 18 fluorodeoxyglucose (FDG) uptake of benign le

31 Fluorine 18 fluorodeoxyglucose (FDG) was mixed with diff

32 acilitate future direct correlations between fluorine 18 fluorodeoxyglucose (FDG)-avid colonic lesion

33 ts suspected of having abdominal or thoracic fluorine 18 fluorodeoxyglucose (FDG)-positive lesions un

34 and consists of imaging the distribution of fluorine 18 fluorodeoxyglucose (FDG).

35 ing of malignancy, bone marrow activity from fluorine 18-fluorodeoxyglucose (FDG) PET may be informat

36 y (PET) using nitrogen-13 (N-13) ammonia and fluorine-18 fluorodeoxyglucose (FDG) for imaging of perf

37 pectively investigated the value of PET with fluorine-18 fluorodeoxyglucose (FDG) for preoperative ch

38 hat positron emission tomography (PET) using fluorine-18 fluorodeoxyglucose (FDG) may be useful for d

39 , and two underwent gallium scintigraphy and fluorine-18 fluorodeoxyglucose (FDG) positron emission t

40 ing optimal interpretative criteria (IC) for Fluorine-18 fluorodeoxyglucose (FDG) Positron Emission T

41 a marker for tissue viability with regional fluorine-18 fluorodeoxyglucose (FDG) uptake in patients

42 Fluorine-18 fluorodeoxyglucose (FDG) with positron emiss

43 There seems to be emerging roles for fluorine-18 fluorodeoxyglucose (FDG)-PET, laparoscopic s

44 We visually compared fluorine-18-fluorodeoxyglucose (FDG)-PET images to radio

45 rves (TACs) from mouse PET studies done with fluorine-18-fluorodeoxyglucose (FDG).

46 Fluorine-18-fluorodeoxyglucose imaging was more accurate

47 olving a labeled dose of 370 MBq (10 mCi) of fluorine 18 fluorodeoxyglucose is estimated to involve a

48 nt contrast material-enhanced MR imaging and fluorine 18 fluorodeoxyglucose PEM in randomized order;

49 y (PET) and coregistered computed tomography/fluorine 18 fluorodeoxyglucose PET are used primarily in

50 rials and Methods Between 2010 and 2013, 219 fluorine 18 fluorodeoxyglucose PET examinations were per

51 etail methods for controlling the quality of fluorine 18 fluorodeoxyglucose PET imaging conditions to

52 Conclusion By using fluorine 18 fluorodeoxyglucose PET of the brain, a deep

53 public data set of multimodality images (CT, fluorine 18 fluorodeoxyglucose PET, and T1-weighted MRI)

54 s gallium 68 DOTA-Tyr3-octreotide PET/CT and fluorine 18 fluorodeoxyglucose PET, play an increasing r

55 t (Fig 1), bilateral breast MRI (Fig 2), and fluorine 18 fluorodeoxyglucose PET/CT (Fig 3) were perfo

56 st without contrast enhancement (Fig 3), and fluorine 18 fluorodeoxyglucose PET/CT (Fig 4).

57 l of 30 lesions were evaluated at (18)F- FDG fluorine 18 fluorodeoxyglucose PET/CT and (18)F- FPPRGD2

58 ure to compare the diagnostic performance of fluorine 18 fluorodeoxyglucose PET/CT and diffusion-weig

59 5 years) who underwent health screening with fluorine 18 fluorodeoxyglucose PET/CT between January 20

60 xaminations, as well as clinically indicated fluorine 18 fluorodeoxyglucose PET/CT examination within

61 trointestinal malignancies underwent two FDG fluorine 18 fluorodeoxyglucose PET/CT examinations withi

62 n lesions presents a further challenge where fluorine 18 fluorodeoxyglucose PET/CT has a potential ro

63 ted MRI is comparable or superior to that of fluorine 18 fluorodeoxyglucose PET/CT in the differentia

64 Conclusion Baseline fluorine 18 fluorodeoxyglucose PET/CT metabolic tumor vo

65 Two hundred eighty-two fluorine 18 fluorodeoxyglucose PET/CT studies in 75 pedi

66 background is recommended in multicenter FDG fluorine 18 fluorodeoxyglucose PET/CT studies on the bas

67 serial cross-sectional imaging (CT, MRI, or fluorine 18 fluorodeoxyglucose PET/CT) between April 201

68 -grade tumors, they were also evaluated with fluorine 18 fluorodeoxyglucose PET/CT, with imaging find

69 nderwent preoperative metabolic imaging with fluorine 18 fluorodeoxyglucose PET/CT.

70 ighted MRI showed significant agreement with fluorine 18 fluorodeoxyglucose PET/MRI for treatment res

71 onclusion A model that includes pretreatment fluorine 18-fluorodeoxyglucose PET texture features from

72 anatomic localization and classification of fluorine 18-fluorodeoxyglucose PET uptake patterns in fo

73 Fluorine-18-fluorodeoxyglucose PET/CT imaging detects tr

74 tudy was to evaluate the prognostic value of fluorine-18-fluorodeoxyglucose PET/CT imaging of venous

75 phic (CT) and (18)F-fluorodeoxyglucose ( FDG fluorine 18 fluorodeoxyglucose ) PET/CT examinations wer

76 ndmark finding relied on the use of clinical fluorine 18 fluorodeoxyglucose positron emission tomogra

77 Fluorine 18 fluorodeoxyglucose positron emission tomogra

78 d 20 nonsmoking control subjects underwent 2 fluorine 18-fluorodeoxyglucose positron emission tomogra

79 erapy with both computed tomography (CT) and fluorine-18 fluorodeoxyglucose positron emission tomogra

80 The prognostic utility of midtreatment fluorine-18 fluorodeoxyglucose positron emission tomogra

81 Fluorine-18 fluorodeoxyglucose positron emission tomogra

82 Functional metabolic imaging through fluorine-18 fluorodeoxyglucose positron emission tomogra

83 The accuracy of fluorine-18-fluorodeoxyglucose positron emission tomogra

84 magnetic resonance imaging and angiography, fluorine-18-fluorodeoxyglucose positron emission tomogra

85 (molecular biology) and imaging diagnostic (fluorine-18 fluorodeoxyglucose-positron emission tomogra

86 es after injection, compared with (18)F- FDG fluorine 18 fluorodeoxyglucose uptake with SUVmax maximu

87 2.3) at 60 minutes, compared with (18)F- FDG fluorine 18 fluorodeoxyglucose uptake with SUVmax maximu

88 hereas vascular inflammation was assessed by fluorine-18 fluorodeoxyglucose uptake on positron emissi

89 ed to segment and quantify serial changes in fluorine-18-fluorodeoxyglucose uptake for veins of inter